Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will begin dosing patients in the next couple of weeks. Despite a recent decline in share price, Bokhari says the group is in execution mode, and has delivered more milestones ahead of schedule.
FSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patients
Quick facts: FSD Pharma
Price: 1.88 CAD
Market Cap: $36.02 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE